Real-World data sought on ribociclib for advanced breast cancer
NCT ID NCT06148506
First seen Jan 10, 2026 · Last updated May 06, 2026 · Updated 19 times
Summary
This study follows 376 people with HR+HER2- advanced breast cancer in Russia to see how well ribociclib combined with hormone therapy or chemotherapy works in everyday medical practice. It does not assign treatments—doctors choose based on routine care. The main goal is to measure how long patients stay on treatment before stopping for any reason, like side effects or disease worsening.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+, HER2-, ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Kaluga, Russia, 248007, Russia
-
Novartis Investigative Site
Barnaul, 656045, Russia
-
Novartis Investigative Site
Chelyabinsk, 454087, Russia
-
Novartis Investigative Site
Irkutsk, 664035, Russia
-
Novartis Investigative Site
Izhevsk, 426009, Russia
-
Novartis Investigative Site
Kemerovo, 650036, Russia
-
Novartis Investigative Site
Krasnodar, 350040, Russia
-
Novartis Investigative Site
Krasnoyarsk, 660022, Russia
-
Novartis Investigative Site
Moscow, 115304, Russia
-
Novartis Investigative Site
Moscow, 115522, Russia
-
Novartis Investigative Site
Moscow, 143423, Russia
-
Novartis Investigative Site
Nal'chik, 360051, Russia
-
Novartis Investigative Site
Podolsk, 142110, Russia
-
Novartis Investigative Site
Saransk, 430032, Russia
-
Novartis Investigative Site
Tambov, 392000, Russia
-
Novartis Investigative Site
Tver', 170008, Russia
-
Novartis Investigative Site
Ufa, 450054, Russia
-
Novartis Investigative Site
Vladikavkaz, 362002, Russia
-
Novartis Investigative Site
Yaroslavl, 150054, Russia
-
Novartis Investigative Site
Yekaterinburg, 620036, Russia
Conditions
Explore the condition pages connected to this study.